Target intelligence / Profile preview

MYC proto-oncogene promoter and 8q24 distal regulatory elements (MYC promoter/8q24 loci)

Target
MYC promoter/8q24 loci
Molecular classification
DNA locus, Regulatory element, Super-enhancer, Gene promoter
01

Overview

The MYC promoter and the 8q24 gene desert DNA loci are essential genomic regions that control the expression of the MYC proto-oncogene, a central driver of cell growth, proliferation, and metabolism (Sur and Taipale, 2016, Nature Reviews Cancer). The 8q24 region is a vast "gene desert" containing multiple tissue-specific super-enhancers that physically interact with the MYC promoter through long-range chromatin looping to modulate its activity (Hnisz et al., 2013, Cell). Within the MYC promoter, the Nuclease Hypersensitive Element III1 (NHE III1) can form secondary DNA structures known as G-quadruplexes, which act as silencers of transcription when stabilized (Brooks et al., 2010, Journal of Clinical Oncology). In many cancers, these loci are hijacked through genomic rearrangements or amplification, leading to the constitutive overexpression of MYC and subsequent oncogenic transformation. Therapeutic targeting of these DNA loci involves small molecules designed to stabilize G-quadruplexes or disrupt the epigenetic landscape of the 8q24 enhancers, thereby reducing MYC output (Siddiqui-Jain et al., 2002, PNAS). However, the ubiquitous requirement for MYC in normal regenerative tissues, such as the bone marrow and intestinal epithelium, poses a significant challenge for achieving a wide therapeutic window.

Other names
8q24 gene desertMYC super-enhancersMYC G-quadruplex DNAC-MYC promoterNHE III1 regionMYC island
02

Mechanism of action

Stabilization of G-quadruplex structures within the promoter to inhibit transcriptional initiation and disruption of long-range enhancer-promoter interactions.

03

Biological functions

Regulation of transcriptionCell cycle controlCell proliferationMetabolic reprogramming
04

Disease associations

CancerProstate cancerBreast cancerColorectal cancerBurkitt lymphoma
05

Safety considerations

Hematologic toxicityGastrointestinal toxicityInhibition of normal regenerative cell proliferationPotential off-target genomic instability
06

Interacting drugs

Pidnarulex (CX-5461)

3 more in the full profile.

07

Biomarkers

MYC amplification8q24 SNP statusMYC mRNA expression levelsMYC protein overexpression

Beyond the preview

Go deeper on MYC proto-oncogene promoter and 8q24 distal regulatory elements (MYC promoter/8q24 loci).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYC proto-oncogene promoter and 8q24 distal regulatory elements (MYC promoter/8q24 loci).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call